Modeling and predicting individual variation in COVID-19 vaccine-elicited antibody response in the general population

Authors:

Abstract
As we learned during the COVID-19 pandemic, vaccines are one of the most important tools in infectious disease control. To date, an unprecedentedly large volume of high-quality data on COVID-19 vaccinations have been accumulated. For preparedness in future pandemics beyond COVID-19, these valuable datasets should be analyzed to best shape an effective vaccination strategy. We are collecting longitudinal data from a community-based cohort in Fukushima, Japan, that consists of 2,407 individuals who underwent serum sampling two or three times after a two-dose vaccination with either BNT162b2 or mRNA-1273. Using the individually reconstructed time courses of the vaccine-elicited antibody response based on mathematical modeling, we first identified basic demographic and health information that contributed to the main features of the antibody dynamics, i.e., the peak, the duration, and the area under the curve. We showed that these three features of antibody dynamics were partially explained by underlying medical conditions, adverse reactions to vaccinations, and medications, consistent with the findings of previous studies. We then applied to these factors a recently proposed computational method to optimally fit an “antibody score”, which resulted in an integer-based score that can be used as a basis for identifying individuals with higher or lower antibody titers from basic demographic and health information. The score can be easily calculated by individuals themselves or by medical practitioners. Although the sensitivity of this score is currently not very high, in the future, as more data become available, it has the potential to identify vulnerable populations and encourage them to get booster vaccinations. Our mathematical model can be extended to any kind of vaccination and therefore can form a basis for policy decisions regarding the distribution of booster vaccines to strengthen immunity in future pandemics.
Funding Information
  • Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research (B) 18H01139)
  • Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research (B) 16H04845)
  • Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research in Innovative Area 20H05042)
  • Japan Agency for Medical Research and Development (AMED Strategic International Brain Science Research Program 22wm0425011s0302)
  • Japan Agency for Medical Research and Development (AMED JP22dm0307009)
  • Japan Agency for Medical Research and Development (AMED CREST 19gm1310002)
  • Japan Agency for Medical Research and Development (AMED Development of Vaccines for the Novel Coronavirus Disease, 21nf0101638h0001)
  • Japan Agency for Medical Research and Development (AMED Development of Vaccines for the Novel Coronavirus Disease, 21nf0101638s0201)
  • Japan Agency for Medical Research and Development (AMED Japan Program for Infectious Disease Research and Infrastructure 22wm0325007h001)
  • Japan Agency for Medical Research and Development (AMED Japan Program for Infectious Disease Research and Infrastructure 22wm0325004s0201)
  • Japan Agency for Medical Research and Development (AMED Japan Program for Infectious Disease Research and Infrastructure 22wm0325015s0301)
  • Japan Agency for Medical Research and Development (AMED Japan Program for Infectious Disease Research and Infrastructure 22wm0325012s0301)
  • Japan Agency for Medical Research and Development (AMED Research Program on Emerging and Re-emerging Infectious Diseases 22fk0108140s0802)
  • Japan Agency for Medical Research and Development (AMED Research Program on HIV/AIDS 22fk0410052s0401)
  • Japan Agency for Medical Research and Development (AMED Program for Basic and Clinical Research on Hepatitis 22fk0210094)
  • Japan Agency for Medical Research and Development (AMED Program on the Innovative Development and the Application of New Drugs for Hepatitis B 22fk0310504h0501)
  • Japan Agency for Medical Research and Development (AMED Research Program on Hepatitis 19fk0210036h0502)
  • Japan Agency for Medical Research and Development (AMED Research Program on Hepatitis 19fk0310114h0103)
  • JST-Mirai Program (JPMJMI22G1)
  • Moonshot Research and Development Program (JPMJMS2021)
  • Moonshot Research and Development Program (JPMJMS2021)
  • Moonshot Research and Development Program (JPMJMS2025)
  • Ministry of Science and ICT, South Korea (NRF grant 2022R1C1C2003637)
  • Shinnihon Foundation of Advanced Medical Treatment Research
  • Secom Science and Technology Foundation
  • The Japan Prize Foundation
  • Kowa Company

This publication has 64 references indexed in Scilit: